For Research Purposes Only — This compound is not FDA approved.

Catalog
BPC-157 / TB-500
Tissue Repair Research

BPC-157 / TB-500

A blend of BPC-157 and TB-500, studied for tissue-repair, angiogenesis, and cell-migration signaling in research models. Premium Research Peptide.

Amount
Quantity
1
Bundle & Save
Only 42 left in stock 18 people viewing now
Est. delivery in 2–5 business days
Free shipment protection
Overnight shipping available

Certificate of Analysis

Third Party Tested Freedom Diagnostics
99.07%
Purity · HPLC-UV
Latest BatchLC-MS IdentityUS Tested
Passed QC panel
Lot WLV10-001Tested Jul 27, 2026
Purity (HPLC-UV)99.07%
Net Peptide Content9.77mg
Identity (LC-MS)BPC-157 / TB-500
Endotoxin (USP <85>)Pass · ≤0.05 EU/mL
Freedom Diagnostics · Independent third-party lab View full COA

Compound Information

Technical specifications
Molecular Profile

What is BPC-157 / TB-500?

TypeSynthetic peptide blend
CAS Number137525-51-0 / 77591-33-4
Molecular Weight1,419.5 / 4,963.4 g/mol
Amino Acids15 + 43
CompositionBPC-157 + TB-500
PubChem Database BPC-157 + TB-500 Research Guide
Storage Requirements

Stability Information

Avoid freeze/thaw cyclesProtect from lightKeep refrigerated
Lyophilized (powder)
−20°C · 24+ months
Reconstituted
2–8°C · ~30 days

Research Background

For laboratory research use only

What this blend contains

This vial holds two unrelated peptides lyophilised together. BPC-157 is a synthetic 15-amino-acid peptide (about 1,419.5 g/mol) whose sequence is taken from a protein found in gastric juice. TB-500 is the name used in the research-supply trade for thymosin beta-4, a 43-amino-acid peptide (about 4,963.4 g/mol) present in most mammalian cells, where its best-characterised role is binding monomeric actin. The two differ more than threefold in size and share no sequence; they are combined here because they are frequently studied in the same experimental models.

What the preclinical literature has examined

  • Actin dynamics and cell migration. Thymosin beta-4 sequesters G-actin, and in vitro scratch and migration assays in endothelial cells and keratinocytes are the classic way its effects have been measured.
  • Angiogenesis assays. Tube-formation and related assays for thymosin beta-4, and studies of growth-factor receptor expression for BPC-157.
  • Rodent injury models. Separate bodies of animal work on each peptide in tendon, muscle, dermal and gastrointestinal models.
  • The combination itself. Published studies of the two peptides together are sparse. Most of what is written about the pairing is extrapolated from the single-compound literature, which is worth knowing when designing an experiment around it.

All of this is preclinical. Neither peptide is an approved drug, and this material is supplied for in vitro and laboratory research only, not for human or veterinary use. The BPC-157 / TB-500 research guide covers both literatures, and the BPC-157 guide goes deeper on that component.

How a blend is characterised

A blend asks more of a Certificate of Analysis than a single peptide does. On an HPLC trace the two components elute as two separate main peaks, and purity describes how much of the total signal belongs to those two peaks as opposed to synthesis by-products. LC-MS identity has to find both molecular masses; confirming one says nothing about the other. Net peptide content is the measured peptide mass in the vial, and it is the figure to use for concentration calculations. The endotoxin result is relevant to any cell-based work. HPLC vs mass spectrometry explains why both methods are needed, and how to read a Certificate of Analysis goes through each line.

Handling in the laboratory

In a blend, the more fragile component sets the rules. Thymosin beta-4 contains a methionine residue that oxidises readily to the sulfoxide, and the oxidised form behaves differently in assays. That makes exposure to air, light and repeated freeze-thaw cycles more costly here than for BPC-157 alone, whose sequence has no methionine, cysteine or tryptophan. Keep the lyophilised powder frozen and dry, reconstitute gently by swirling, refrigerate solutions, and divide a stock into single-use aliquots on the day it is made. Because the two peptides cannot be separated once dissolved, any concentration calculated from the vial applies to the mixture. See peptide storage and stability and how to reconstitute a research peptide.

Common questions

Is TB-500 the same as thymosin beta-4?

TB-500 is the name commonly used in the research-supply trade. The component in this blend is specified as a 43-amino-acid peptide with CAS number 77591-33-4, which corresponds to thymosin beta-4. The LC-MS identity result on the Certificate of Analysis confirms the masses present.

Are BPC-157 and TB-500 related peptides?

No. They share no sequence and differ more than threefold in size: BPC-157 has 15 amino acids and thymosin beta-4 has 43. They are supplied together because they are often studied in the same preclinical models.

Is this blend approved for human use?

No. Neither peptide is an approved drug. This material is sold for in vitro and laboratory research only and is not for human or veterinary use.

How is a two-peptide blend verified?

HPLC should show two main peaks, one per component, and LC-MS should find both molecular masses. Net peptide content gives the measured peptide mass in the vial. Each of these is reported on the Certificate of Analysis for the lot.

Why does this blend need more careful handling than BPC-157 alone?

Thymosin beta-4 contains a methionine residue that oxidises easily. Keep the powder frozen and dry, protect solutions from light and air, and use single-use aliquots instead of repeated freeze-thaw cycles.

Frequently Researched Together

Important Research Notice

Not for human consumption. This product is sold exclusively for research and educational purposes. It is not intended to diagnose, treat, cure, or prevent any disease.

By purchasing, you confirm that you are a qualified researcher and will use these products in accordance with all applicable laws and regulations.